Filippo Martinelli-Boneschi

List of Publications by Year
in descending order

145 papers	12,909 citations	50566 48 h-index	29333 108 g-index
151 all docs	151 docs citations	151 times ranked	25170 citing authors

#	Article	IF	Citations
1	Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study. Frontiers in Medicine, 2022, 9, 834354.	1.2	22
2	COVIDâ€19 vaccination hesitancy among people with chronic neurological disorders: A position paper. European Journal of Neurology, 2022, 29, 2163-2172.	1.7	13
3	A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility. Journal of Neurology, 2022, 269, 4510-4522.	1.8	2
4	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	1.4	46
5	The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. International Journal of Cardiology, 2021, 324, 249-254.	0.8	21
6	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	2.8	370
7	The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults. Journal of Clinical Medicine, 2021, 10, 686.	1.0	2
8	Posterior reversible encephalopathy syndrome and COVID-19: A series of 6 cases from Lombardy, Italy. ENeurologicalSci, 2021, 22, 100306.	0.5	17
9	Assessment of the genetic contribution to brain magnetic resonance imaging lesion load and atrophy measures in multiple sclerosis patients. European Journal of Neurology, 2021, 28, 2513-2522.	1.7	2
10	Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility. Journal of Genetics and Genomics, 2021, 48, 497-507.	1.7	3
11	Long-Term Coronavirus Disease 2019 Complications in Inpatients and Outpatients: A One-Year Follow-up Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab384.	0.4	47
12	Impact of SARS-CoV-2 infection on acute intracerebral haemorrhage in northern Italy. Journal of the Neurological Sciences, 2021, 426, 117479.	0.3	0
13	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86
14	An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients. Genes, 2021, 12, 1607.	1.0	4
15	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110590.	0.5	1
16	Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population. Frontiers in Genetics, 2021, 12, 800262.	1.1	3
17	A pharmacogenetic study implicates NINJ2 in the response to Interferon-Î² in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1074-1082.	1.4	5
18	The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation. Leukemia, 2020, 34, 257-270.	3.3	33

#	Article	IF	Citations
19	Evaluation of molecular inversion probe versus TruSeqÂ® custom methods for targeted next-generation sequencing. PLoS ONE, 2020, 15, e0238467.	1.1	17
20	Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation. Medicina (Lithuania), 2020, 56, 572.	0.8	14
21	Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. Multiple Sclerosis Journal, 2020, 26, 1268-1269.	1.4	35
22	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
23	Impact of multiple sclerosis risk loci in postinfectious neurological syndromes. Multiple Sclerosis and Related Disorders, 2020, 44, 102326.	0.9	2
24	Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 591395.	1.1	4
25	Functional and structural plasticity following action observation training in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1472-1487.	1.4	26
26	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, .	6.0	710
27	Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. PLoS Genetics, 2019, 15, e1008180.	1.5	46
28	Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis. Cells, 2019, 8, 262.	1.8	9
29	Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 155-164.	4.9	63
30	Response to the commentary â€œThe effect of C9orf72 intermediate repeat expansions in neurodegenerative and autoimmune diseasesâ€•by Biasiotto G and Zanella I.âœ°. Multiple Sclerosis and Related Disorders, 2019, 27, 79-80.	0.9	1
31	Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. European Journal of Neurology, 2018, 25, 934.	1.7	18
32	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment. Multiple Sclerosis Journal, 2018, 24, 459-471.	1.4	105
33	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 1507-1510.	1.4	11
34	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	13.5	115
35	Neuromyelitis optica spectrum disorder and multiple sclerosis in a Sardinian family. Multiple Sclerosis and Related Disorders, 2018, 25, 73-76.	0.9	4
36	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. Acta Neurologica Scandinavica, 2018, 138, 447-453.	1.0	4

#	Article	IF	Citations
37	Laser capture microdissection for transcriptomic profiles in human skin biopsies. BMC Molecular Biology, 2018, 19, 7.	3.0	7
38	No C9orf72 repeat expansion in patients with primary progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 192-195.	0.9	9
39	Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis. Annals of Neurology, 2018, 84, 51-63.	2.8	38
40	Pharmacogenetic study of long-term response to interferon-Î² treatment in multiple sclerosis. Pharmacogenomics Journal, 2017, 17, 84-91.	0.9	31
41	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics Journal, 2017, 17, 312-318.	0.9	28
42	COL6A5variants in familial neuropathic chronic itch. Brain, 2017, 140, aww343.	3.7	25
43	Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis. Scientific Reports, 2017, 7, 43718.	1.6	35
44	Early involvement of cellular stress and inflammatory signals in the pathogenesis of tubulointerstitial kidney disease due to UMOD mutations. Scientific Reports, 2017, 7, 7383.	1.6	33
45	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2017, 8, 321.	2.2	30
46	Assessing Functional Decline in Neurological Diseases Clinical Trials: Duration of Follow-Up - The Case of Multiple Sclerosis. Frontiers of Neurology and Neuroscience, 2016, 39, 93-100.	3.0	1
47	CHRNA7 Gene and Response to Cholinesterase Inhibitors in an Italian Cohort of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2016, 52, 1203-1208.	1.2	18
48	Unraveling gene expression profiles in peripheral motor nerve from amyotrophic lateral sclerosis patients: insights into pathogenesis. Scientific Reports, 2016, 6, 39297.	1.6	24
49	HIF-1Î± regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood, 2016, 127, 1987-1997.	0.6	52
50	Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurology: Genetics, 2016, 2, e87.	0.9	76
51	Next Generation Sequencing of Pooled Samples: Guideline for Variantsâ€™ Filtering. Scientific Reports, 2016, 6, 33735.	1.6	81
52	Power estimation for non-standardized multisite studies. NeuroImage, 2016, 134, 281-294.	2.1	36
53	Efficacy and safety of nabiximols (SativexÂ®) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurological Sciences, 2016, 37, 235-242.	0.9	38
54	Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e129.	3.1	18

#	Article	IF	Citations
55	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	3.1	19
56	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain, 2015, 138, 632-643.	3.7	54
57	NLRP3 inflammasome is associated with the response to IFN-Î² in patients with multiple sclerosis. Brain, 2015, 138, 644-652.	3.7	93
58	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1431-1442.	1.4	27
59	Mitochondrial DNA sequence variation in multiple sclerosis. Neurology, 2015, 85, 325-330.	1.5	60
60	A pharmacogenetic study implicates <scp>SLC9a9</scp> in multiple sclerosis disease activity. Annals of Neurology, 2015, 78, 115-127.	2.8	39
61	Inverse correlation of genetic risk score with age at onset in bout-onset and progressive-onset multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1463-1467.	1.4	13
62	Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics, 2015, 47, 1107-1113.	9.4	312
63	The burden of multiple sclerosis variants in continental Italians and Sardinians. Multiple Sclerosis Journal, 2015, 21, 1385-1395.	1.4	10
64	Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. Oncogene, 2015, 34, 2094-2102.	2.6	72
65	The mirror neuron system and the strange case of Broca's area. Human Brain Mapping, 2015, 36, 1010-1027.	1.9	37
66	Prostaglandin D2 synthase/GPR44: a signaling axis in PNS myelination. Nature Neuroscience, 2014, 17, 1682-1692.	7.1	66
67	Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1633-1640.	1.4	59
68	Advances in Neuroimmunology: From Bench to Bedside. Autoimmune Diseases, 2014, 2014, 1-2.	2.7	0
69	A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes and Immunity, 2014, 15, 126-132.	2.2	26
70	Predictors of effectiveness of multidisciplinary rehabilitation treatment on motor dysfunction in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 862-870.	1.4	11
71	Multiple sclerosis progression is not associated with birth timing in Italy. Journal of the Neurological Sciences, 2014, 346, 194-196.	0.3	1
72	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811.	1.4	11

#	Article	IF	Citations
73	Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. Neurological Sciences, 2014, 35, 789-791.	0.9	8
74	Peripheral nerve morphogenesis induced by scaffold micropatterning. Biomaterials, 2014, 35, 4035-4045.	5.7	39
75	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2014, 3, 520-526.	0.9	34
76	Transmembrane Protein 106B Gene (TMEM106B) Variability and Influence on Progranulin Plasma Levels in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 757-761.	1.2	2
77	Genetics can contribute to the prognosis of Brugada syndrome: a pilot model for risk stratification. European Journal of Human Genetics, 2013, 21, 911-917.	1.4	58
78	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360.	9.4	1,213
79	Astrocytes acquire resistance to iron-dependent oxidative stress upon proinflammatory activation. Journal of Neuroinflammation, 2013, 10, 130.	3.1	29
80	The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. Journal of Neuroimmunology, 2013, 260, 99-106.	1.1	88
81	Mitoxantrone for multiple sclerosis. The Cochrane Library, 2013, , CD002127.	1.5	75
82	Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiology of Aging, 2013, 34, 1711.e7-1711.e13.	1.5	43
83	Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls. American Journal of Human Genetics, 2013, 92, 854-865.	2.6	164
84	Clinical and <scp>MRI</scp> predictors of response to interferonâ€beta and glatiramer acetate in relapsingâ€“remitting multiple sclerosis patients. European Journal of Neurology, 2013, 20, 1060-1067.	1.7	27
85	DDIT4/REDD1/RTP801 Is a Novel Negative Regulator of Schwann Cell Myelination. Journal of Neuroscience, 2013, 33, 15295-15305.	1.7	51
86	A Strong Anti-Inflammatory Signature Revealed by Liver Transcription Profiling of Tmprss6â^'/â^' Mice. PLoS ONE, 2013, 8, e69694.	1.1	8
87	Association of Genetic Markers with CSF Oligoclonal Bands in Multiple Sclerosis Patients. PLoS ONE, 2013, 8, e64408.	1.1	27
88	Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2284-93.	3.3	39
89	CSF metabolites in the differential diagnosis of Alzheimerâ€™s disease from frontal variant of frontotemporal dementia. Neurological Sciences, 2012, 33, 973-977.	0.9	10
90	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. Neuroscience Letters, 2012, 530, 155-160.	1.0	17

#	Article	IF	Citations
91	Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1. Neuromuscular Disorders, 2012, 22, 219-224.	0.3	51
92	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neuroscience Letters, 2012, 508, 4-8.	1.0	95
93	Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacological Research, 2012, 65, 472-479.	3.1	40
94	A genome-wide association study in progressive multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1384-1394.	1.4	57
95	De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nature Genetics, 2012, 44, 1030-1034.	9.4	345
96	Short and Long Term Variation in Ultraviolet Radiation and Multiple Sclerosis. International Journal of Environmental Research and Public Health, 2012, 9, 685-697.	1.2	11
97	Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 30, 745-749.	1.2	35
98	LETTER TO THE EDITOR. Brain Pathology, 2012, 22, 79-79.	2.1	1
99	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219.	13.7	2,400
100	An APOE Haplotype Associated with Decreased Îµ4 Expression Increases the Risk of Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 235-245.	1.2	58
101	Oxidative Imbalance in Different Neurodegenerative Diseases with Memory Impairment. Neurodegenerative Diseases, 2011, 8, 129-137.	0.8	37
102	Role of OLR1 and Its Regulating hsa-miR369-3p in Alzheimer's Disease: Genetics and Expression Analysis. Journal of Alzheimer's Disease, 2011, 26, 787-793.	1.2	31
103	MGAT5 and disease severity in progressive multiple sclerosis. Journal of Neuroimmunology, 2011, 230, 143-147.	1.1	9
104	Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis. Journal of Neurology, 2011, 258, 835-839.	1.8	21
105	Genomeâ€wide metaâ€analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology, 2011, 70, 897-912.	2.8	314
106	Role of hnRNP-A1 and miR-590-3p in Neuronal Death: Genetics and Expression Analysis in Patients with Alzheimer Disease and Frontotemporal Lobar Degeneration. Rejuvenation Research, 2011, 14, 275-281.	0.9	57
107	Failure to Replicate an Association of rs5984894 SNP in the PCDH11X Gene in a Collection of 1,222 Alzheimer's Disease Affected Patients. Journal of Alzheimer's Disease, 2010, 21, 385-388.	1.2	11
108	MGAT5 alters the severity of multiple sclerosis. Journal of Neuroimmunology, 2010, 220, 120-124.	1.1	72

#	Article	IF	Citations
109	IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity, 2010, 11, 397-405.	2.2	70
110	GRN Variability Contributes to Sporadic Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2010, 19, 171-177.	1.2	28
111	Immunoproteasome LMP2 60HH Variant Alters MBP Epitope Generation and Reduces the Risk to Develop Multiple Sclerosis in Italian Female Population. PLoS ONE, 2010, 5, e9287.	1.1	56
112	Comparative study of mitoxantrone efficacy profile in patients with relapsingâ€"remitting and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1490-1499.	1.4	26
113	Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. Genes and Immunity, 2010, 11, 497-503.	2.2	17
114	Human glioma tumors express high levels ofÂtheÂchemokine receptor CX3CR1. European Cytokine Network, 2010, 21, 27-33.	1.1	26
115	Lifetime and actual prevalence of pain and headache in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 514-521.	1.4	97
116	Absence of angiogenic genes modification in Italian ALS patients. Neurobiology of Aging, 2008, 29, 314-316.	1.5	41
117	A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1076-1083.	1.4	77
118	Evaluation of Polyneuropathy Markers in Type 1 Diabetic Kidney Transplant Patients and Effects of Islet Transplantation. Diabetes Care, 2007, 30, 3063-3069.	4.3	98
119	Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?. Journal of Neuro-Oncology, 2007, 84, 71-77.	1.4	17
120	Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiology of Aging, 2006, 27, 770.e1-770.e5.	1.5	54
121	Linkage Analysis and Disease Models in Benign Familial Infantile Seizures: A Study of 16 Families. Epilepsia, 2006, 47, 1029-1034.	2.6	23
122	Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects. Journal of Neurology, 2006, 253, 1399-1403.	1.8	22
123	Motor evoked potentials in a mouse model of chronic multiple sclerosis. Muscle and Nerve, 2006, 33, 265-273.	1.0	25
124	Evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurology, The, 2005, 4, 75-76.	4.9	8
125	Immunological patterns identifying disease course and evolution in multiple sclerosis patients. Journal of Neuroimmunology, 2005, 165, 192-200.	1.1	38
126	Vascular endothelial growth factor gene variability is associated with increased risk for AD. Annals of Neurology, 2005, 57, 373-380.	2.8	115

#	Article	IF	Citations
127	Surgery for intracranial meningiomas in the elderly: a clinicalâ€"radiological grading system as a predictor of outcome. Journal of Neurosurgery, 2005, 102, 290-294.	0.9	69
128	Movement preparation is affected by tissue damage in multiple sclerosis: Evidence from EEG event-related desynchronization. Clinical Neurophysiology, 2005, 116, 1515-1519.	0.7	22
129	No evidence of ATP1A2 involvement in 12 multiplex Italian families with benign familial infantile seizures. Neuroscience Letters, 2005, 388, 71-74.	1.0	8
130	Pharmacogenetics of autoimmune diseases: Research issues in the case of Multiple Sclerosis and the role of IFN-Î². Journal of Autoimmunity, 2005, 25, 1-5.	3.0	15
131	The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials. Multiple Sclerosis Journal, 2004, 10, 341-347.	1.4	20
132	The 129 codon polymorphism of the Prion Protein gene influences earlier cognitive performance in Down syndrome subjects. Journal of Neurology, 2003, 250, 688-692.	1.8	29
133	Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Multiple Sclerosis Journal, 2003, 9, 349-355.	1.4	72
134	Interleukin-1B polymorphism is associated with age at onset of Alzheimerâ€™s disease. Neurobiology of Aging, 2003, 24, 927-931.	1.5	75
135	An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. Multiple Sclerosis Journal, 2003, 9, 467-471.	1.4	27
136	Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study. Journal of the Neurological Sciences, 2002, 194, 71-74.	0.3	60
137	Evidence and age-related distribution of mtDNA D-loop point mutations in skeletal muscle from healthy subjects and mitochondrial patients. Journal of the Neurological Sciences, 2002, 202, 85-91.	0.3	42
138	Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia, 2002, 39, 105-113.	2.5	112
139	Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. Journal of Neurology, 2002, 249, 305-311.	1.8	100
140	Four New Families with Autosomal Dominant Partial Epilepsy with Auditory Features: Clinical Description and Linkage to Chromosome 10q24. Epilepsia, 2002, 43, 60-67.	2.6	59
141	Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nature Genetics, 2002, 30, 335-341.	9.4	555
142	Fatigue in Multiple Sclerosis Is Associated with Abnormal Cortical Activation to Voluntary Movementâ€"EEG Evidence. NeuroImage, 2001, 13, 1186-1192.	2.1	136
143	Retrospective study of a large population of patients affected with mitochondrial disorders: clinical, morphological and molecular genetic evaluation. Journal of Neurology, 2001, 248, 778-788.	1.8	45
144	Association study of a new polymorphism in the PECAM-1 gene in multiple sclerosis. Journal of Neuroimmunology, 2000, 104, 174-178.	1.1	19

#	Article	IF	Citations
145	MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatique. Journal of Neurology, 2000, 247, 506-509.	1.8	122